Obtained $1.04 billion settlement in whistleblower case over misrepresentation of Advair
Plaintiff(s):
U.S. ex rel. Graydon
Case type / claims:
Whistleblower action under the False Claims Act alleging that GlaxoSmithKline misrepresented the safety and efficacy of its blockbuster asthma and COPD drug, Advair, leading to inflated government reimbursements. The case was part of a broader federal investigation into GSK’s unlawful marketing practices.
Defendant(s):
GlaxoSmithKline
Jurisdiction:
U.S. District Court for the District of Massachusetts
Year:
2012
Outcome:
- Settled for $1.04 billion as part of a global resolution of federal and state False Claims Act allegations.
